Literature DB >> 28833087

Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium.

Ana Babic1, Holly R Harris2, Allison F Vitonis3, Linda J Titus4, Susan J Jordan5, Penelope M Webb5, Harvey A Risch6, Mary Anne Rossing2,7, Jennifer A Doherty8, Kristine Wicklund2, Marc T Goodman9,10, Francesmary Modugno11,12,13,14, Kirsten B Moysich15, Roberta B Ness16, Susanne K Kjaer17,18, Joellen Schildkraut19, Andrew Berchuck20, Celeste L Pearce21,22, Anna H Wu22, Daniel W Cramer3,23, Kathryn L Terry3,23.   

Abstract

Menstrual pain, a common gynecological condition, has been associated with increased risk of ovarian cancer in some, but not all studies. Furthermore, potential variations in the association between menstrual pain and ovarian cancer by histologic subtype have not been adequately evaluated due to lack of power. We assessed menstrual pain using either direct questions about having experienced menstrual pain, or indirect questions about menstrual pain as indication for use of hormones or medications. We used multivariate logistic regression to calculate the odds ratio (OR) for the association between severe menstrual pain and ovarian cancer, adjusting for potential confounders and multinomial logistic regression to calculate ORs for specific histologic subtypes. We observed no association between ovarian cancer and menstrual pain assessed by indirect questions. Among studies using direct question, severe pain was associated with a small but significant increase in overall risk of ovarian cancer (OR = 1.07, 95% CI: 1.01-1.13), after adjusting for endometriosis and other potential confounders. The association appeared to be more relevant for clear cell (OR = 1.48, 95% CI: 1.10-1.99) and serous borderline (OR = 1.31, 95% CI: 1.05-1.63) subtypes. In this large international pooled analysis of case-control studies, we observed a small increase in risk of ovarian cancer for women reporting severe menstrual pain. While we observed an increased ovarian cancer risk with severe menstrual pain, the possibility of recall bias and undiagnosed endometriosis cannot be excluded. Future validation in prospective studies with detailed information on endometriosis is needed.
© 2017 UICC.

Entities:  

Keywords:  case-control studies; inflammation; menstrual pain; ovarian cancer

Mesh:

Year:  2017        PMID: 28833087      PMCID: PMC7580880          DOI: 10.1002/ijc.31010

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  39 in total

1.  Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Mei-Chiung Shih; Daniel W Cramer
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

2.  Incessant ovulation--a factor in ovarian neoplasia?

Authors:  M F Fathalla
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

3.  Menstrual pain and epithelial ovarian cancer risk.

Authors:  Ana Babic; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2014-09-05       Impact factor: 2.506

4.  Retrograde menstruation in healthy women and in patients with endometriosis.

Authors:  J Halme; M G Hammond; J F Hulka; S G Raj; L M Talbert
Journal:  Obstet Gynecol       Date:  1984-08       Impact factor: 7.661

5.  Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea.

Authors:  M C Rees; A B Anderson; L M Demers; A C Turnbull
Journal:  Br J Obstet Gynaecol       Date:  1984-07

6.  Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea.

Authors:  S Nigam; C Benedetto; M Zonca; I Leo-Rossberg; H Lübbert; J Hammerstein
Journal:  Eicosanoids       Date:  1991

7.  Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.

Authors:  Melissa A Merritt; Adèle C Green; Christina M Nagle; Penelope M Webb
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

8.  Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman
Journal:  Epidemiology       Date:  2008-03       Impact factor: 4.822

9.  Menopausal hormone therapy and risk of epithelial ovarian cancer.

Authors:  Mary Anne Rossing; Kara L Cushing-Haugen; Kristine G Wicklund; Jennifer A Doherty; Noel S Weiss
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

10.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.

Authors:  Celeste Leigh Pearce; Claire Templeman; Mary Anne Rossing; Alice Lee; Aimee M Near; Penelope M Webb; Christina M Nagle; Jennifer A Doherty; Kara L Cushing-Haugen; Kristine G Wicklund; Jenny Chang-Claude; Rebecca Hein; Galina Lurie; Lynne R Wilkens; Michael E Carney; Marc T Goodman; Kirsten Moysich; Susanne K Kjaer; Estrid Hogdall; Allan Jensen; Ellen L Goode; Brooke L Fridley; Melissa C Larson; Joellen M Schildkraut; Rachel T Palmieri; Daniel W Cramer; Kathryn L Terry; Allison F Vitonis; Linda J Titus; Argyrios Ziogas; Wendy Brewster; Hoda Anton-Culver; Alexandra Gentry-Maharaj; Susan J Ramus; A Rebecca Anderson; Doerthe Brueggmann; Peter A Fasching; Simon A Gayther; David G Huntsman; Usha Menon; Roberta B Ness; Malcolm C Pike; Harvey Risch; Anna H Wu; Andrew Berchuck
Journal:  Lancet Oncol       Date:  2012-02-22       Impact factor: 41.316

View more
  2 in total

1.  Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6.

Authors:  Mi Gong; Chengyan Luo; Huangyang Meng; Siyue Li; Sipei Nie; Yi Jiang; Yicong Wan; Huijian Li; Wenjun Cheng
Journal:  Onco Targets Ther       Date:  2019-11-20       Impact factor: 4.147

2.  Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk.

Authors:  Naoko Sasamoto; Ana Babic; Allison F Vitonis; Linda Titus; Daniel W Cramer; Britton Trabert; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Prev Res (Phila)       Date:  2021-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.